Key Insights

Highlights

Success Rate

78% trial completion

Published Results

23 trials with published results (42%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 47/100

Termination Rate

16.4%

9 terminated out of 55 trials

Success Rate

78.0%

-8.5% vs benchmark

Late-Stage Pipeline

2%

1 trials in Phase 3/4

Results Transparency

72%

23 of 32 completed with results

Key Signals

23 with results78% success

Data Visualizations

Phase Distribution

54Total
Not Applicable (16)
Early P 1 (2)
P 1 (14)
P 2 (21)
P 3 (1)

Trial Status

Completed32
Terminated9
Active Not Recruiting7
Withdrawn4
Not Yet Recruiting1
Recruiting1

Trial Success Rate

78.0%

Benchmark: 86.5%

Based on 32 completed trials

Clinical Trials (55)

Showing 20 of 20 trials
NCT03880422Not ApplicableRecruiting

Nutrition and Exercise Interventions for Androgen Deprivation Therapy-Induced Obese Frailty in Elderly and Non-Elderly Survivors of Advanced Prostate Cancer

NCT02346253Not ApplicableActive Not Recruiting

High-Dose Brachytherapy in Treating Patients With Prostate Cancer

NCT02296229Not ApplicableActive Not Recruiting

Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer

NCT04589468Not ApplicableActive Not Recruiting

Researching the Effect of Exercise on Cancer

NCT06811454Not ApplicableNot Yet Recruiting

Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET)

NCT01923506Phase 1Active Not Recruiting

Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery

NCT02023463Phase 1Active Not Recruiting

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

NCT03963739Completed

Effect of Treatment on Work Experience in Patients With Stage I-III Prostate Cancer

NCT04007770Phase 2Active Not Recruiting

Acupuncture Pilot Study for Cancer-related Cognitive Function

NCT02278185Phase 2Completed

Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer

NCT02603965Phase 1Completed

Copper Cu 64 TP3805 PET in Detecting Cancer in Patients With Prostate Cancer Undergoing Surgery

NCT03477864Phase 1WithdrawnPrimary

Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer

NCT01823562Phase 1Active Not Recruiting

Aborption and Metabolism of Lyophilized Black Raspberry Food Products in Men With Prostate Cancer Undergoing Surgery

NCT03103321Phase 3Completed

Decision Aids in Improving Knowledge in Patients With Newly Diagnosed Prostate Cancer

NCT05025748Not ApplicableCompleted

Ask Questions (ASQ):Implementation of a Communication Intervention

NCT01555632Not ApplicableWithdrawn

Atorvastatin Calcium in Preventing Metabolic Syndrome in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy

NCT02048150Phase 1Completed

Intra-operative Optical Imaging With MDX1201-A488 in Patients With Prostate Cancer

NCT01385059Phase 2CompletedPrimary

Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer

NCT02420652Phase 2Terminated

Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy

NCT02217709Phase 2Completed

Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer

Scroll to load more

Research Network

Activity Timeline